HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jeffrey L. Port Michael E. Burt Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Port, J. L. Articles by Burt, M. E. Search for Related Content PubMed PubMed Citation Articles by Port, J. L. Articles by Burt, M. E.

Ann Thorac Surg 1995;60:239-243
© 1995 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Buthionine Sulfoximine Pretreatment Potentiates the Effect of Isolated Lung Perfusion With Doxorubicin

The Thoracic Oncology/Surgical Metabolism Laboratory, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

Background. Although surgical resection remains the mainstay of treatment for metastatic pulmonary sarcoma, 5-year survival approaches only 25%. Chemotherapy has been limited by tumor resistance and systemic toxicity. We assessed the efficacy of L-buthionine-SR-sulfoximine, an inhibitor of glutathione synthesis, as a sensitizer for isolated lung perfusion.

Methods. In experiment 1, sarcoma-bearing rats (n = 20) received either buthionine sulfoximine via intraperitoneal injection or Hespan. After the last injection, tumor glutathione levels were measured. In experiment 2, rats (n = 60) were injected with sarcoma intravenously. On day 6, animals were pretreated with either buthionine sulfoximine or Hespan intraperitoneally. On day 7, rats underwent isolated lung perfusion (Hespan or doxorubi-cin) or intravenous therapy (Hespan or doxorubicin). On day 14, tumor nodules were counted.

Results. Buthionine sulfoximine effectively depleted tumor glutathione. Animals treated with intravenous therapy had no response to therapy, whereas those animals treated with doxorubicin isolated lung perfusion alone had a limited response. Buthionine-sulfoximine pretreatment in combination with doxorubicin isolated lung perfusion led to a 13-fold reduction in tumor nodules and 5 complete responses.

Conclusions. Buthionine-sulfoximine pretreatment in combination with doxorubicin isolated lung perfusion is superior to intravenous doxorubicin and doxorubicin isolated lung perfusion alone for the treatment of metastatic pulmonary sarcoma.

This article has been cited by other articles:

				P. E. Van Schil, J. M. Hendriks, B. P. van Putte, B. A. Stockman, P. R. Lauwers, P. W. ten Broecke, M. J. Grootenboers, and F. M. Schramel Isolated lung perfusion and related techniques for the treatment of pulmonary metastases Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 487 - 496. [Abstract] [Full Text] [PDF]

				R. Lee, C. H.R. Boasquevisque, M. M. Boglione, M. Hiratsuka, R. K. Scheule, J. D. Cooper, and G. A. Patterson Isolated lung liposome-mediated gene transfer produces organ-specific transgenic expression Ann. Thorac. Surg., September 1, 1998; 66(3): 903 - 907. [Abstract] [Full Text] [PDF]

				J. L. Port, B. Ng, J. L. Ellis, S. Nawata, J. T. Lenert, and M. E. Burt Isolated Lung Perfusion With FUDR in the Rat: Pharmacokinetics and Survival Ann. Thorac. Surg., September 1, 1996; 62(3): 848 - 852. [Abstract] [Full Text]

				B. Ng, S. N. Hochwald, and M. E. Burt Isolated Lung Perfusion With Doxorubicin Reduces Cardiac and Host Toxicities Associated With Systemic Administration Ann. Thorac. Surg., March 1, 1996; 61(3): 969 - 972. [Abstract] [Full Text]